Gene
CCND2
CCND2 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (14), Actionable biomarkers (2), Trial mentions (8), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention CCND2. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 3 at the structurally incomplete recent edge.
CCND2 has 8 trial mentions across 8 years. That is too few to read as a trend, so the years are listed instead.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 1 of 8,597 | 0.01% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 8 of 11,460 | 0.07% |
| 2022 | 1 of 8,285 | 0.01% | 11 of 13,598 | 0.08% |
| 2021 | 0 of 8,692 | 0.00% | 13 of 15,045 | 0.09% |
| 2020 | 0 of 7,640 | 0.00% | 15 of 14,459 | 0.10% |
| 2019 | 1 of 7,300 | 0.01% | 13 of 12,159 | 0.11% |
| 2018 | 1 of 6,927 | 0.01% | 9 of 11,854 | 0.08% |
| 2017 | 1 of 6,558 | 0.02% | 8 of 11,595 | 0.07% |
Showing 10 of 37 years.
Assay-provider ledger (14)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| AB Applied Biosystems | Reagent supplier | Clinical validationAnalytical validation | 2 | February 28, 2017 |
| QIAGEN | Reagent supplier | Clinical validationAnalytical validation | 2 | February 28, 2017 |
| Ankara University Biotechnology Institute Central Laboratory | Not a company | Clinical validationAnalytical validation | 1 | December 13, 2016 |
| Invitrogen | Reagent supplier | Clinical validationAnalytical validation | 1 | December 13, 2016 |
| ROCHE | Context dependent | Clinical validationAnalytical validation | 1 | December 13, 2016 |
Showing 5 of 14 assay-provider companies.
Actionable biomarkers (2)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| CCND2 amplification | Palbociclib | response-associated | lung carcinoma | Cancer Genome Interpreter |
| CCND2 amplification | Cdk4/6 Inhibitors | response-associated | No disease recorded | Cancer Genome Interpreter |
Trial mentions (8)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT05843253 | Trial eligibility (AACT) |
| NCT02523014 | Trial eligibility (AACT) |
| NCT04040205 | Trial eligibility (AACT) |
| NCT02896335 | Trial eligibility (AACT) |
| NCT03452774 | Trial eligibility (AACT) |
Showing 5 of 8 trial mentions.
Target-disease associations (774)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 3-methylglutaconic aciduria type 4 | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| 46,XX gonadal dysgenesis | endocrine system disease | Mouse knockout (IMPC) |
| 46,XX ovotesticular disorder of sex development | endocrine system disease | Mouse knockout (IMPC) |
| 46,XX sex reversal 1 | endocrine system disease | Mouse knockout (IMPC) |
| 46,XX testicular disorder of sex development | endocrine system disease | Mouse knockout (IMPC) |
Showing 5 of 774 associations.
Vendor sourcing (37)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is not observed in the gnomAD v2.1.1 dataset. Predicted Consequence/Location: Stop-gained (nonsense): predicted to result in a loss or disruption... | View ClinVar record SCV005903735.1 |
| Abramson Cancer Center | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : \- Disease Characteristics: All Subjects: All subjects treated under this protocol will have histologically documented cancer of one of the following typ... | View trial NCT01037790 |
| Abramson Cancer Center | Trial sponsor | Mentioned in trial textTrial free-text mention | CCND2 | View trial NCT01037790 |
| Alliance for Clinical Trials in Oncology | Trial sponsor | Mentioned in trial textTrial free-text mention | CCND2 | View trial NCT02523014 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.665C>T (p.S222L) alteration is located in exon 4 (coding exon 4) of the CCND2 gene. This alteration results from a C to T substitution at nucleotide po... | View ClinVar record SCV003550072.2 |
Showing 5 of 37 sourcing records.
Trial-cited literature (149)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I). | JCO precision oncology | 2024 | 16 |
| A Phase I Study of the CDK4/6 Inhibitor Palbociclib in Combination with Cetuximab and Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2024 | 15 |
| Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling. | Haematologica | 2024 | 5 |
| The Intergenic Type LncRNA (LINC RNA) Faces in Cancer with In Silico Scope and a Directed Lens to LINC00511: A Step toward ncRNA Precision. | Non-coding RNA | 2023 | 49 |
| The immune microenvironment shapes transcriptional and genetic heterogeneity in chronic lymphocytic leukemia. | Blood advances | 2023 | 42 |
Showing 5 of 149 papers.
Protein variant mentions (6)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.K270* | 1 | 2015 | PMID 25741868 |
| p.Q277* | 1 | 2015 | PMID 25741868 |
| p.R262H | 1 | 2015 | PMID 25741868 |
| p.R86S | 1 | 2021 | PMID 33046516 |
| p.S1Q | 1 | 2016 | PMID 27916527 |
Showing 5 of 6 variants.
Literature-extracted relations (19)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Neoplasms | Disease | associate |
Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I). | 2024 |
| Multiple Myeloma | Disease | associate |
Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling. | 2024 |
| Neoplasms | Disease | associate |
Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials. | 2023 |
| Neoplasms | Disease | associate |
Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial. | 2021 |
| Prostatic Neoplasms | Disease | associate |
A novel DNA methylation score accurately predicts death from prostate cancer in men with low to intermediate clinical risk factors. | 2016 |
Showing 5 of 19 relation assertions.
Organizations publishing (260)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Harvard Medical School | Academic | 9 | 2009 to 2022 |
| Dana-Farber Cancer Institute | Other | 6 | 2014 to 2022 |
| Government of the United States of America | Government | 6 | 2011 to 2024 |
| Mayo Clinic | Hospital | 6 | 2009 to 2024 |
| University of London | Academic | 5 | 2011 to 2018 |
Showing 5 of 260 organizations.
Where CCND2 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- infectious disease
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- reproductive system or breast disease
- urinary system disease
722 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.